Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent-Reference-Cited by-同舟云学术

Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent

Published:2023-06-01 Issue:5 Volume:39 Page:332-346
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Roy Chowdhury Uttio¹,Pervan-Steel Cynthia L.²,Sheeler Ryan³,Sookdeo Hemchand K.²,Rogers Brian⁴,Casale Ralph²,Dosa Peter I.⁵,Htoo Thurein²,Wirostko Barbara M.²⁶,Fautsch Michael P.¹^ORCID

Affiliation:

1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.

2. Qlaris Bio, Inc., Dedham, Massachusetts, USA.

3. NorthEast BioLab, Hamden, Connecticut, USA.

4. Pacific BioDevelopment, LLC, Emeryville, California, USA.

5. Institute for Therapeutics Discovery and Development, Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, USA.

6. Department of Ophthalmology, Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

https://www.liebertpub.com/doi/pdf/10.1089/jop.2022.0184

Reference27 articles.

1. The number of people with glaucoma worldwide in 2010 and 2020

2. Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040

3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures

4. The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration

5. Reduction of Intraocular Pressure and Glaucoma Progression